Inventiva

32 articles with Inventiva

• 

  BioSpace Global Roundup, Oct. 3

  10/3/2019

  Companies from across the globe share information on their business and pipelines.
• 

  BioSpace Global Roundup, Sept. 26

  9/26/2019

  Companies from across the globe share updates on their business and pipelines.
• 

  BioSpace Global Roundup, Sept. 12

  9/12/2019

  Companies and organizations from across Europe, Asia and North America share updates on their business and pipelines.
• 

  BioSpace Global Roundup, Sept. 5

  9/5/2019

  Companies from across Europe and Asia share updates on their business and pipelines.
• 

  BioSpace Global Roundup, Aug. 29

  8/29/2019

  Companies from across the globe provide updates on their business and pipelines.
• 

  BioSpace Global Roundup, Aug. 22

  8/22/2019

  Companies from across the globe provide updates on their business and pipelines.
• 

  BioSpace Global Roundup, June 13

  6/13/2019

  Companies from across the globe share business and pipeline updates.
• 

  BioSpace's Global Biopharma Roundup: April 25

  4/25/2019

  Companies across Europe and Asia provide information about deal, clinical trials and more, with news from Synaptive Medical, Epic, Inventiva, Velabs, and more.
• 

  Inventiva Discontinues Systemic Sclerosis Drug After Mid-Stage Flop

  2/19/2019

  Shares of France-based Inventiva have plunged more than 45 percent after the company reported that its experimental treatment for a rare autoimmune disease failed to hit primary and secondary endpoints in a mid-stage trial.

• Inventiva to Present at Two Upcoming Investor Conferences

  11/13/2017

  Inventiva today announced that Frédéric Cren, CEO of Inventiva, will present at two upcoming investor conferences.

• Inventiva: Third-Quarter 2017 Financial Information

  11/7/2017

  Revenues of €6.0 million, an increase of 4.6% compared to 2016

• Inventiva’s Phase IIb FASST Trial In Systemic Sclerosis With Lanifibranor Completes Enrollment

  10/17/2017

  Inventiva announced that it has completed the enrollment of its Phase IIb FASST (For A Systemic Sclerosis Treatment) trial in Systemic Sclerosis (SSc) with lanifibranor, formerly known as IVA337.

• Inventiva: First-Half 2017 Results

  9/27/2017

• Inventiva’s IVA337 Given Generic Name "Lanifibranor" By WHO

  9/19/2017

• Inventiva And AbbVie Extend Agreement To Discover New Potent Orally-Available Small Molecule Ror? Inverse Agonist Drug Candidates

  9/6/2017

• Inventiva Announces Exercise Of Option By Boehringer Ingelheim To Jointly Develop Potential New Treatments For Idiopathic Pulmonary Fibrosis (IPF)

  9/5/2017

• Inventiva Release: Odiparcil Awarded Orphan Drug Designation For The Treatment Of MPS VI By The FDA

  8/14/2017

• Inventiva To Present New Data On IVA337 At The 15th International Workshop On Scleroderma Research In Pittsburgh, USA

  7/31/2017

• Inventiva Announces First-Half 2017 Financial And Corporate Update

  7/6/2017

• Inventiva Announces New Compelling Data On Odiparcil / IVA336 To Be Presented At MPS Society National Conference

  6/30/2017